NewAmsterdam Pharma Company N.V.
NAMS
$35.26
-$0.59-1.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -98.18% | 542.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -98.18% | 542.88% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -98.18% | 542.88% | |||
| SG&A Expenses | -10.06% | 0.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.30% | -23.81% | |||
| Operating Income | -54.74% | 48.30% | |||
| Income Before Tax | -314.68% | 56.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -314.68% | 56.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -314.68% | 56.07% | |||
| EBIT | -54.74% | 48.30% | |||
| EBITDA | -54.76% | 48.33% | |||
| EPS Basic | -313.04% | 56.96% | |||
| Normalized Basic EPS | -313.33% | 60.93% | |||
| EPS Diluted | -313.04% | 56.96% | |||
| Normalized Diluted EPS | -313.33% | 60.93% | |||
| Average Basic Shares Outstanding | 0.37% | 2.09% | |||
| Average Diluted Shares Outstanding | 0.37% | 2.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||